NCT07042620 2026-04-16
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
SonoClear AS
Phase NA Recruiting
Clinical Trials
432 trialsNCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT04762069 2026-04-15
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT06641908 2026-04-15
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono
Phase 1 Recruiting
NCT06805305 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT07185880 2026-04-14
STAR-GBM
Myosin Therapeutics Inc.
Phase 1/2 Recruiting
NCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT04988750 2026-04-13
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NaviFUS Corporation
Phase NA Completed
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT06910306 2026-04-06
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT07497373 2026-04-03
JL15003
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT03975829 2026-04-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT05986851 2026-03-31
Azeliragon in MGMT Unmethylated Glioblastoma
Cantex Pharmaceuticals
Phase 2 Active not recruiting
NCT06650605 2026-03-31
CITADEL-123
Ariceum Therapeutics GmbH
Phase 1 Completed
NCT04471844 2026-03-30
EF-32
NovoCure Ltd.
Phase NA Completed
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT07431216 2026-03-30
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Starlight Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT07501559 2026-03-30
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Jecho Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT05303467 2026-03-27
FRONTIER
Boston Scientific Corporation
Phase 1 Recruiting
NCT02586857 2026-03-25
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT03551249 2026-03-20
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
Phase NA Completed
NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
NCT05283330 2026-03-20
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Phase 1 Recruiting
NCT07464925 2026-03-20
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT07225621 2026-03-19
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04678648 2026-03-18
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
Phase 1 Recruiting
NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
NCT06926075 2026-03-17
ADVICE
Filamon LTD
Phase 1/2 Recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT07455045 2026-03-06
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT07195591 2026-03-04
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT07346144 2026-03-04
ADePT
Trogenix ltd
Phase 1/2 Not yet recruiting
NCT02704858 2026-03-02
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT05938387 2026-02-18
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
CureVac
Phase 1 Completed
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT04485949 2026-02-10
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
Phase 2 Active not recruiting